The tumor microenvironment significantly influences therapeutic response and clinical
outcome. Microenvironment-mediated drug resistance can be induced by soluble factors …

Drug resistance is a major obstacle in the field of pre-clinical and clinical therapeutics. The
development of novel technologies and targeted therapies have yielded new modalities to …

Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM
include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors …

Multiple myeloma is a plasma cell malignancy characterized by complex heterogeneous
cytogenetic abnormalities. The bone marrow microenvironment promotes multiple myeloma …

The antiangiogenic activity of thalidomide (Thal), coupled with an increase in bone marrow
angiogenesis in multiple myeloma (MM), provided the rationale for the use of Thal in MM …

Purpose: The success of bortezomib therapy for treatment of multiple myeloma (MM) led to
the development of structurally and pharmacologically distinct novel proteasome inhibitors …

Thalidomide (Thal) can overcome drug resistance in multiple myeloma (MM) but is
associated with somnolence, constipation, and neuropathy. In previous in vitro studies, we …

There appear to be 2 pathways involved in the early pathogenesis of premalignant
monoclonal gammopathy of undetermined significance (MGUS) and malignant multiple …

Increased angiogenesis has recently been recognized in active multiple myeloma (MM).
Since vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) …

Novel agents, including the proteasome inhibitor bortezomib, have significantly improved
the response and survival of patients with multiple myeloma over the last decade. Despite …